U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1998.
[_] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________to_____________.
Commission file number: 0-23153
VOLU-SOL, INC.
--------------
(Exact name of small business issuer as specified in its charter)
UTAH 87-0543981
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
5095 WEST 2100 SOUTH
SALT LAKE CITY, UTAH 84120
(Address of principal executive offices) (Zip Code)
(801) 974-9474
(Issuer's telephone number, including area code)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [X] No [_]
As of July 31, 1998, the registrant had issued and outstanding 2,111,216 shares
of Common Stock, par value $.0001.
Transitional Small Business Disclosure Format (Check One):
Yes [X] No [_]
TABLE OF CONTENTS
Page No.
--------
PART I. FINANCIAL INFORMATION
1. Financial Statements
Unaudited Condensed Consolidated Balance Sheet as of June 30, 1998...................... 3
Unaudited Condensed Consolidated Statements of Operations
for the Three Months and Nine Months Ended June 30, 1998 and 1997...................... 4
Unaudited Condensed Consolidated Statements of Cash Flows
for the Nine Months Ended June 30, 1998 and 1997........................................ 5
Notes to Unaudited Condensed Consolidated Financial Statements.......................... 6
2. Management's Discussion and Analysis or Plan of Operation............................... 8
PART 2. OTHER INFORMATION....................................................................... 11
Page 2
VOLU-SOL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEET
(UNAUDITED)
ASSETS
As of June 30,
1998
--------------
Current assets:
Cash $ 30,097
Accounts receivable, net 70,689
Inventories 167,701
--------------
Total current assets 268,487
Property and equipment, net 205,975
Other assets, net 34,214
--------------
Total assets $ 508,676
==============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Note payable - Biomune Systems, Inc. $ 272,644
Accounts payable 70,771
Preferred stock dividends payable 38,620
Accrued interest payable 7,759
Other accrued liabilities 91,221
--------------
Total current liabilities 481,015
--------------
Shareholders' equity:
Series A Convertible Preferred Stock, 3,658.25 shares
outstanding and 4,500 shares subscribed 1,661,304
Common Stock, 2,111,216 shares outstanding 211
Additional paid-in capital 2,200,600
Accumulated deficit (2,934,454)
Stock subscriptions receivable (900,000)
--------------
Total shareholders' equity 27,661
--------------
Total liabilities and shareholders' equity $ 508,676
==============
The accompanying notes are an integral part of this condensed consolidated
balance sheet.
VOLU-SOL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three Months For the Nine Months
Ended June 30 Ended June 30
--------------------------------- ---------------------------------
1998 1997 1998 1997
-------------- -------------- -------------- --------------
REVENUES $ 143,809 $ 133,294 $ 381,097 $ 368,731
-------------- -------------- -------------- --------------
OPERATING EXPENSES:
Cost of revenues 104,503 126,256 322,844 356,830
Selling, general and administrative 184,042 187,723 535,149 487,564
-------------- -------------- -------------- --------------
Total operating expenses 288,545 313,979 857,993 844,394
-------------- -------------- -------------- --------------
LOSS FROM OPERATIONS (144,736) (180,685) (476,896) (475,663)
OTHER INCOME (EXPENSE):
Interest income 1,536 - 4,081 -
Interest expense (Biomune Systems, Inc.) (7,826) - (27,432) -
-------------- -------------- -------------- --------------
NET LOSS (151,026) (180,685) (500,247) (475,663)
Preferred Stock dividends (18,290) - (38,620) -
Preferred Stock accretion of beneficial
conversion feature - - (166,750) -
-------------- -------------- -------------- --------------
NET LOSS APPLICABLE TO COMMON SHARES $ (169,316) $ (180,685) $ (705,617) $ (475,663)
============== ============== ============== ==============
NET LOSS PER COMMON SHARE (BASIC AND
DILUTED -- See Note 5) $ (0.08) $ (0.09) $ (0.33) $ (0.23)
============== ============== ============== ==============
WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING (See Note 6) 2,111,216 2,111,216 2,111,216 2,111,216
VOLU-SOL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Increase (Decrease) in Cash
For the Nine Months
Ended June 30
1998 1997
----------------- --------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (500,247) $ (475,663)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation and amortization 59,771 51,361
Changes in assets and liabilities:
Accounts receivable, net (6,478) 7,491
Inventories (14,813) (78,260)
Other assets (12,140) 50
Accounts payable 23,805 74,678
Accrued liabilities (5,260) (4,143)
----------------- --------------------
Net cash used in operating activities (455,362) (424,486)
----------------- --------------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment (4,376) (1,700)
----------------- --------------------
Net cash used in investing activities (4,376) (1,700)
----------------- --------------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Net change in former Parent's investment - 260,124
Loan from Biomune Systems, Inc. - 264,500
Principal repayment on loan from Biomune Systems, Inc. (117,856) -
Proceeds from issuance of Series A Preferred Stock
net of offering costs 270,000 -
----------------- --------------------
Net cash provided by financing activities 152,144 524,624
----------------- --------------------
NET (DECREASE) INCREASE IN CASH (307,594) 98,438
CASH AND AT BEGINNING OF THE YEAR. 337,691 12,167
----------------- --------------------
CASH AT END OF THE PERIOD. $ 30,097 $ 110,605
================= ====================
During the nine months ended June 30, 1998, the Company accrued Series A
Preferred Stock dividends of $38,620 and accreted $166,750 related to the
beneficial conversion feature of the Series A Preferred stock to Common Stock.
During the nine months ended June 30, 1998, the Company issued 250 shares of
Series A Preferred Stock with a fair maket value of $50,000, as determined by
the Board of Directors, as commissions related to the sale of Series A Preferred
Stock.
The accompanying notes are an integral part of these condensed consolidated
statements of cash flows.
VOLU-SOL, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(1) PRESENTATION OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The accompanying unaudited condensed consolidated financial statements of Volu-
Sol, Inc. and Volu-Sol Reagents Corporation, its wholly owned subsidiary
(collectively, the "Company"), have been prepared in accordance with generally
accepted accounting principles for interim financial information in accordance
with the instructions to Form 10-QSB and Item 310 of Regulation S-B.
Accordingly, such unaudited financial statements do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of management, all
adjustments, consisting only of normal recurring adjustments, necessary to
present fairly the financial position, results of operations and cash flows of
the Company for the interim periods presented, have been included. Operating
results for the three and nine months ended June 30, 1998 are not necessarily
indicative of the results that may be expected for the year ending September 30,
1998. The Company suggests that these condensed consolidated financial
statements be read in conjunction with the financial statements and notes
thereto included in the Company's Form 10-KSB for the year ended September 30,
1997.
The Company has determined that certain freight and overhead expenditures were
more appropriately classified as a component of cost of goods sold in its
interim financial statements. Certain reclassifications have been made to prior
periods information in order to be consistent with the three and nine months
presentations.
(2) RELATED-PARTY TRANSACTIONS
From March 5, 1997 through September 30, 1997, the Company obtained loans from
Biomune Systems, Inc. (the Company's former parent, "Biomune") totaling
$390,500, of which $272,644 remains outstanding as of June 30, 1998. These
loans bear interest at an annual rate of ten percent and are due on demand.
Accrued but unpaid interest on these loans totaled $7,759 and is included in
"accrued interest payable" in the accompanying condensed consolidated balance
sheet as of June 30, 1998. The Company anticipates repaying this debt from the
proceeds raised in a private placement of the Company's Series A Preferred Stock
(see Notes 4 and 6).
(3) INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out method) or
market value. Inventories consist of the following as of June 30, 1998:
Raw materials, packaging and supplies $ 54,460
113,241
Instruments, biological stains and reagents -----------
$ 167,701
===========
(4) SERIES A PREFERRED STOCK
As of June 30, 1998, the Company has $900,000 of subscriptions receivable from
the sale of 4,500 shares of Series A Preferred Stock. During the nine months
ended June 30, 1998, the Company sold 1,500 shares of Series A Preferred Stock
for $300,000 in cash. The Series A Preferred Stock became convertible into
Page 6
Common Stock beginning January 1, 1998. The "conversion price," which is the
basis for such conversion, is the lesser of (i) 80 percent of the average
closing bid price of the Company's Common Stock for the three trading days
immediately preceding the date of conversion or (ii) $1.25 per share. This
beneficial conversion feature has been recognized as an increase to net loss
applicable to common shares of $166,750 for the nine months ended June 30, 1998.
The investor that subscribed to 6,000 shares of the Company's Series A Preferred
at $200 per share has paid $300,000 of that $1,200,000 subscription. The
investor has notified the Company that it will pay the $900,000 balance of its
subscription at such time as the Company becomes listed on a stock exchange (See
Note 6).
During the nine months ended June 30, 1998, the Company paid commissions of
$55,000 to MK Financial, Inc., an entity benficially owned by David G. Derrick,
a shareholder of the Company, and issued a total of 250 shares of preferred
stock as commissions to two individuals in connection with the sale of Series A
Preferred Stock.
(5) NET LOSS PER COMMON SHARE
Basic net loss per common share ("Basic EPS") excludes dilution and is computed
by dividing net loss by the weighted average number of common shares outstanding
during the period. Diluted net loss per common share ("Diluted EPS") reflects
the potential dilution that could occur if stock options or other contracts to
issue Common Stock including convertible Preferred Stock were exercised or
converted into Common Stock. The computation of Diluted EPS does not assume
exercise or conversion of securities that would have an anti-dilutive effect on
net loss per common share. Because the Company has incurred a loss for the
periods presented, no exercises or conversions have been considered as they
would be anti-dilutive, thereby decreasing the net loss applicable to common
shares.
At June 30, 1998, there were outstanding options to purchase 743,601 shares of
Common Stock and there were 3,658.25 shares of Series A Preferred Stock
convertible into a minimum of 585,320 shares of Common Stock, neither of which
are included in the computation of Diluted EPS because they would be anti-
dilutive (see Note 6).
(6) SUBSEQUENT EVENTS
Common Stock
The Company is in the process of listing on the OTC Electronic Bulletin Board
and expects that process to be completed in August 1998. The process has been
delayed due to the Nasdaq Stock Markets' posting of an ex-dividend date for the
distribution of the Company's Common Stock in connection with the divestiture of
the Company by Biomune that differed from the ex-dividend date previously
selected and announced by Biomune. Biomune had previously set the record and
dividend date for the divestiture to be March 5, 1997. However, Nasdaq advised
some brokers that the record date was February 11, 1998, the approximate date
Volu-Sol shares were mailed to Biomune shareholders. This resulted in
confusion concerning who was entitled to receive shares of the Company's Common
Stock. To allow for its shares to be included on the OTC Electronic Bulletin
Board, the Company has agreed with Biomune to issue additional dividend shares
of the Company's Common Stock. Therefore, a total of 3,115,436 shares of Common
Stock will be issued to shareholders of record as of February 11, 1998 as
additional dividend shares. Following the distribution of the additional
dividend shares, there will be 5,226,652 shares of Common Stock issued and
outstanding.
Page 7
Preferred Stock
As of July 31, 1998 the Company sold 125 shares of Series A Preferred Stock at
$200 per share to an accredited investor in an exempt transaction for total
proceeds of $25,000.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
Until October 1, 1997, the Company was a division and then a wholly owned
subsidiary of Biomune. Effective October 1, 1997, Biomune divested itself of the
Company by distributing Volu-Sol Common Stock to holders of record of Biomune
Common Stock as of March 5, 1997 and since October 1, 1997, the Company has
operated as a separate entity. The following discussion and analysis should be
read in conjunction with the Company's unaudited condensed consolidated
financial statements and the notes thereto contained elsewhere in this report.
The discussion of these results should not be construed to imply that any
condition or circumstance discussed herein will necessarily continue in the
future.
When used in this report, the words "believes," "anticipates," "expects,"
and similar expressions are intended to identify forward-looking statements.
Such statements are subject to certain risks and uncertainties that could cause
actual results to differ materially from those projected. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to publicly
release the results of any revisions to these forward-looking statements that
may be made to reflect events or circumstances after the date of this report, or
to reflect the occurrence of unanticipated events.
RESULTS OF OPERATIONS
Three Months Ended June 30, 1998 and 1997
During the three months ended June 30, 1998, the Company generated revenues
totaling $143,809 compared to $133,294 for the three months ended June 30, 1997.
This increase in revenues is attributable to the increased sales of reagents and
a price increase implemented in March 1998.
Cost of revenues for the quarter ended June 30, 1998 totaled $104,503,
compared to $126,256 for the three months ended June 30, 1997. The overall gross
margin for the third quarter of fiscal 1998 was 27% of revenues compared to 5%
of revenues for the comparable period in 1997. The increase in the gross margin
on sales of stains and reagents is attributable to shipping charges that are now
being paid by customers as well as a price increase that was implemented in
March 1998. Also, the increased gross margin results from a continued effort to
create a leaner production team and better inventory management.
Selling, general and administrative expenses totaled $184,042 for the three
months ended June 30, 1998, compared to $187,723 for comparable period in 1997,
an overall decrease of $3,681. This decrease is primarily attributable to
decreased selling and marketing expenditures resulting from a reduction in
staffing in these areas, partially offset by an increase resulting from a
severance package granted to the company's former President and in professional
fees and other costs associated with the registration of the Company's Common
Stock under federal securities laws and the distribution of its shares in
connection with the divestiture of the Company by Biomune.
Interest expense increased to $7,826 for the three months ended June 30,
1998 from $0 for the comparable period in 1997. The increase in interest
expense is due to borrowings from Biomune, the Company's former President.
Page 8
The Company incurred a net loss applicable to common shares of $169,316 for
the three months ended June 30, 1998 compared to a net loss applicable to common
shares of $180,685 for the three months ended June 30, 1997. This decrease is
due primarily to the increase in revenues and gross margin previously discussed.
It is anticipated that the net loss applicable to common shareholders will
increase in the future due to dividend requirements and accretion of the
beneficial conversion feature associated with the consummation of additional
sales of Series A Preferred Stock. As of June 30, 1998, the Company had
remaining subscriptions receivable totaling $900,000. If only those
subscriptions are collected and no further sales of Series A Preferred Stock are
made, the net loss applicable to common shares would increase by approximately
$225,000 for the one-time charge related to the beneficial conversion feature
and by approximately $90,000 per year for recurring dividends at 10 percent.
Sales of Series A Preferred Stock could be as high as $2,400,000, in which case
the dividends and the impact of the beneficial conversion feature would increase
accordingly.
Nine Months Ended June 30, 1998 and 1997
During the nine months ended June 30, 1998, the Company generated revenues
totaling $381,097 compared to $368,731 for the nine months ended June 30, 1997.
This increase in revenues is primarily attributable to the increased sales in
Volu-Sol reagents and a price increase implemented in March 1998.
Cost of revenues for the nine months ended June 30, 1998 totaled $322,844
compared to $356,830 for the nine months ended June 30, 1997. The overall gross
margin for the nine months ended March 31, 1998 is 15 percent compared to 3
percent in 1997. The increase in the gross margin on sales of stains and
reagents is attributable to shipping charges that are now being paid by
customers as well as a price increase that was implemented in March 1998. Also,
the increased gross margin results from a continued effort to create a leaner
production team and better inventory management.
Selling, general and administrative expenses totaled $535,149 for the nine
months ended June 30, 1998, compared to $487,564 for the nine months ended June
30, 1997, an overall increase of $47,585. This increase is due to expenses
associated with the registration of the Company's Common Stock under federal
securities laws and the distribution of its shares in connection with the
divestiture of the Company by Biomune and to increased employee expenditures in
the form of a severance package granted to the Company's former President.
Interest expense increased from $0 for the nine months ended June 30, 1997
to $27,432 for the nine months ended June 30, 1998. The increase in interest
expense is due to borrowings from Biomune, the Company's former parent.
The Company incurred a net loss applicable to common shares of $705,617 for
the nine months ended June 30, 1998 compared to a net loss applicable to common
shares of $475,663 for the nine months ended June 30, 1997. This increase in
net loss is primarily due to dividends and accretion of the beneficial
conversion feature related to the Series A Preferred Stock as well as an
increase in selling, general and administrative expenses.
Page 9
LIQUIDITY AND CAPITAL RESOURCES
The Company currently is unable to finance its operations solely from its
cash flows from operating activities. From October 1, 1993 through September
30, 1997, Biomune financed the Company's operations through a series of loans
and other capital contributions totaling approximately $2,800,000. Of this
amount, $390,500 represents loans which bear interest at the rate of ten percent
per year and which are payable on demand. Since the divestiture of the Company
by Biomune, the Company has not received additional funds from Biomune in the
form of loans or equity contributions. The Company intends to sell up to 12,000
shares of its Series A Preferred Stock in a private offering ("Offering"), for
total proceeds of up to $2,400,000. There can be no assurance that the Company
will be successful in its efforts to sell any part of the shares. The Series A
Preferred Stock is convertible into Common Stock of the Company. The
"conversion price" which is the basis for such conversion is the lesser of (i)
80 percent of the average closing bid price of the Company's Common Stock for
the three trading days immediately preceding the date of conversion or (ii)
$1.25 per share. As of June 30, 1998, the Company had received subscriptions
for $1,575,000 of Series A Preferred Stock, for which cash of $675,000 had been
received. The remaining $900,000 subscription receivable will be collected when
the Company becomes listed on the OTC Electronic Bulletin Board. There can be
no assurance that the Company's stock will become traded on the OTC Electronic
Bulletin Board or that if it does become listed that a market will develop for
such stock.
As of June 30, 1998, the Company had cash of $30,097 and negative working
capital of $212,528 compared to cash of $337,691 and positive working capital of
$38,083 as of September 30, 1997.
During the nine months ended June 30, 1998, the Company's operating
activities used cash of $455,361, much of which was provided by the sale of
Series A Preferred Stock. During the nine months ended June 30, 1997, the
Company's operating activities used cash in the amount of $424,486, which was
provided primarily by capital contributions from Biomune.
The Company has no credit facility with any commercial lending institution.
In the past, the Company has borrowed and received capital from time to time
from Biomune, but the Company has no formal financing arrangement, agreement or
understanding with Biomune or any other party to provide debt financing in the
future.
The unaudited condensed consolidated financial statements of the Company
have been prepared on the assumption that the Company will continue as a going
concern. The Company's product line is limited and it has been necessary to
rely upon borrowings and financing from the sale of its equity securities to
sustain operations. Additional financing will be required if the Company is to
continue as a going concern. If such additional funding cannot be obtained, the
Company may be required to scale back or discontinue its operations. Even if
such additional financing is available to the Company, there can be no assurance
that it will be on terms favorable to the Company. In any event, such financing
will result in immediate and possible substantial dilution to existing
shareholders.
Year 2000 Issues
- ----------------
The Year 2000 Issue is the result of computer programs being written using
two digits rather than four to define the applicable year. Any of the Company's
computer programs that have date-sensitive software may recognize a date using
"00" as the year 1900, rather than the year 2000. This could result in a system
failure or miscalculations causing disruptions of operations, including, among
other things, a temporary inability to process transactions, send invoices, or
engage in similar normal business activities.
Page 10
The Company relies on computer hardware, software and related technology,
together with data, in the operation of its business. Such technology and data
are used in the Company's internal operations, such as billing and accounting.
The Company has not completed its investigation of the technology and data used
in its operations and has yet to determine whether its business will be affected
by Year 2000 Issues. The Company intends to evaluate its technology and data to
determine what, if any, remedial action may be required to address theses
issues. This includes remediating any Year 2000 Issues that are related to the
Company's customers, suppliers and distributors, but there can be no assurance
that such third parties will successfully remediate their own Year 2000 Issues
over which the Company has no control.
The Company believes it will substantially complete its evaluation and
remediation prior to the commencement of the year 2000, and that upon
substantial completion of such actions, and assuming that the Company's
customers, suppliers and distributors successfully remediate their own Year 2000
Issues over which the Company has no control, the Company will have no material
business risk from such issues.
The total cost of such an evaluation and any necessary remediation has not
yet been determined by the Company.
Forward-looking Statements and Certain Risk Factors
- ---------------------------------------------------
Statements which are not historical facts contained in this report are
forward-looking statements. Section 27A of the Securities Act of 1933, as
amended, provides a safe harbor for forward-looking statements. In order to
comply with the terms of the safe harbor, the Company cautions that a variety of
factors could cause the Company's actual results to differ materially from
anticipated results or other expectations expressed in this report. The
forward-looking statements contained in this Management's Discussion and
Analysis or Plan of Operation involve a number of risks and uncertainties that
could cause actual results to differ from projected or anticipated results. The
risk factors discussed in Part I, Item 1 ("Business") and in the "Management's
Discussion and Analysis or Plan of Operation" (Item 6) of the Company's Annual
Report on Form 10-KSB for the fiscal year ended September 30, 1997 may also
affect actual operating results.
Page 11
PART II - OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES
Unregistered sales of equity securities during quarter (other than in
reliance on Regulation S).
Recent Sales of Unregistered Securities. Subsequent to the end of the
---------------------------------------
period covered by this Report, the Company issued equity securities that were
not registered under the Securities Act of 1933, as amended (the "Act").
Specifically, the Company issued 125 shares of Series A Preferred Stock to one
accredited investor for gross proceeds to the Company of $25,000. The Company
issued such shares without registration under the Act in reliance on Section
4(2) of the Act. The shares of Series A Preferred Stock were issued as
restricted securities and the certificates representing such shares were stamped
with a restrictive legend to prevent any resale without registration under the
Act or compliance with an exemption. These shares are convertible to shares of
Common Stock of the Company under certain circumstances. No conversions have
been made to date.
Subsequent to the end of the period covered by this report, the Company
agreed to issue an additional 3,115,436 shares of Common Stock as additional
dividend shares in connection with the divestiture of the Company and to satisfy
the impact of Nasdaq's selection of February 11, 1998 as the ex-dividend date,
despite the Company's selection of March 5, 1997 as the ex-dividend date of the
divestiture. All shares issued in connection with the divestiture, including
additional dividend shares, were issued without registration pursuant to
exemptions from registration of such transactions from the Act applicable to
spin-off transactions.
ITEM 3. OTHER INFORMATION
In accordance with recent amendments to Rule 14a-4, 14a-5 and 14a-8 under
the Securities Exchange Act of 1934, as amended ("Exchange Act"), written notice
of stockholder proposals outside the procedures of Rule 14a-8 for consideration
at the 1999 annual meeting of stockholders must be received by the Company on or
before April 30, 1999 in order to be considered timely for purposes of Rule 14a-
4. The persons designated in the Company's proxy statement and management proxy
card will be granted discretionary authority with respect to any stockholder
proposal with respect to which the Company does not receive timely notice.
ITEM 4. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits Required by Item 601 of Regulation S-B
No reports on Form 8-K were filed by the Company during the quarter
ended June 30, 1998.
Exhibit No. Description
----------- -----------
27 Financial Data Schedule
Page 12
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
VOLU-SOL, INC.
Date: August 13, 1998 By: /s/ W. W. Kirton, III
-------------------------------
Wilford W. Kirton, III,
Chief Executive Officer
Date: August 13, 1998 By: /s/ Michael G. Acton
-------------------------------
Michael G. Acton,
Acting Principal Accounting Officer
Page 13